Latest News
Category: News
Telix Pharmaceuticals Limited and China Grand Pharma Announce Strategic Licence and Commercial Partnership for Greater China...
Read more
Telix Pharmaceuticals provides its Activity Report and Appendix 4C for the quarter ending 30th September 2020, and Q3 2020 sales update for its prostate cancer imaging...
Read more
Telix Japan is pleased to announce it will be presenting at the Annual Scientific Meeting of the Japanese Society of Nuclear Medicine (JSNM-JSNMT2020) to be held 12-14th November 2020 at...
Read more
Telix has secured an exclusive Intellectual Property licence agreement with the German Cancer Research Center (DKFZ) for a novel imaging technology in the field of image-guided surgery for prostate...
Read more
Telix Pharmaceuticals Japan K.K. is pleased to announce the completion of Phase I enrolment of the Company’s Phase I/II ZIRDAC-JP study of Telix’s renal cancer diagnostic imaging product TLX250-CDx (89Zr-girentuximab)...
Read more
Telix and Eczacıbaşı-Monrol Nuclear Products Co. are pleased to announce that the first patients have been dosed in Telix’s Phase III ZIRCON clinical...
Read more
Telix sponsored a session at the recent EANM20 Satellite Symposium, entitled “Next Generation Imaging with PSMA-PET & More”. For those unable to attend, we are pleased to provide recordings of...
Read more
Telix Pharmaceuticals is pleased to announce we are participating at AusBiotech + Invest 2020 online conference to be held live 28th – 30th October 2020 and on-demand. Telix is pleased...
Read more
Telix Pannounces FDA has granted Orphan Drug Designation (ODD) for O-(2-[18F]fluoroethyl)-L-tyrosine for PET imaging of...
Read more
Telix Pharmaceuticals submits NDA to US FDA for TLX591-CDx (Kit for the preparation of...
Read more